Get the Stockscreener App
74.31
2.21%
-1.68
After Hours:
74.31
Mirum Pharmaceuticals Inc stock is traded at $74.31, with a volume of 336.39K.
It is down -2.21% in the last 24 hours and up +14.82% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$75.99
Open:
$76.11
24h Volume:
336.39K
Relative Volume:
0.55
Market Cap:
$3.73B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-46.09
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
-2.30%
1M Performance:
+14.82%
6M Performance:
+65.02%
1Y Performance:
+80.67%
1-Day Range:
$74.26
$76.87
1-Week Range:
$73.70
$78.09
52-Week Range:
$36.86
$78.09
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
74.31 | 3.76B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Woodline Partners LP Acquires 161,867 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Adage Capital Partners GP L.L.C. Purchases 195,000 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week HighWhat's Next? - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighHere's Why - MarketBeat
Eventide Asset Management LLC Sells 79,938 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals at Morgan Stanley Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Mirum Pharmaceuticals announces enrollment completion in the phase 2b Vistas study - MarketScreener
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study - Business Wire
Published on: 2025-09-08 12:42:47 - beatles.ru
Mirum Pharmaceuticals, Inc. $MIRM Holdings Increased by Frazier Life Sciences Management L.P. - MarketBeat
Multi factor analysis applied to Mirum Pharmaceuticals Inc.Weekly Investment Report & Stock Portfolio Risk Management - Newser
Is Mirum Pharmaceuticals Inc. stock overvalued or fairly priced2025 Geopolitical Influence & Short-Term High Return Ideas - خودرو بانک
Cubist Systematic Strategies LLC Grows Stake in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsEarnings Trend Report & Safe Entry Trade Signal Reports - خودرو بانک
Can Mirum Pharmaceuticals Inc. reach resistance levels soon2025 EndofYear Setup & Fast Gain Swing Alerts - خودرو بانک
Real time scanner hits for Mirum Pharmaceuticals Inc. explainedBond Market & AI Driven Stock Movement Reports - Newser
Sentiment analysis tools applied to Mirum Pharmaceuticals Inc.2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
Is Mirum Pharmaceuticals Inc. forming a reversal patternPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Published on: 2025-09-05 14:03:50 - Newser
Signal strength of Mirum Pharmaceuticals Inc. stock in tech scannersQuarterly Risk Review & Safe Capital Growth Stock Tips - Newser
Chart overlay techniques for tracking Mirum Pharmaceuticals Inc.Earnings Performance Report & Capital Efficiency Focused Ideas - Newser
Rafferty Asset Management LLC Raises Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Will Mirum Pharmaceuticals Inc. stock recover after recent dropMarket Movement Recap & Detailed Earnings Play Alerts - Newser
Using Ichimoku Cloud for Mirum Pharmaceuticals Inc. technicalsQuarterly Profit Summary & Low Drawdown Trading Techniques - Newser
Mirum Pharmaceuticals at Cantor Global: Financial Independence and Growth By Investing.com - Investing.com Canada
Regression analysis insights on Mirum Pharmaceuticals Inc. performanceWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
What to do if you’re stuck in Mirum Pharmaceuticals Inc.July 2025 Analyst Calls & Daily Technical Forecast Reports - Newser
What is the next catalyst for Mirum Pharmaceuticals Inc.Trade Risk Report & Safe Capital Growth Stock Tips - خودرو بانک
Mirum Pharmaceuticals stock reaches all-time high of 75.8 USD By Investing.com - Investing.com Australia
Can Mirum Pharmaceuticals Inc. benefit from deglobalization2025 Valuation Update & Weekly Market Pulse Updates - خودرو بانک
What technical models suggest about Mirum Pharmaceuticals Inc.’s comeback2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
Kodai Capital Management LP Takes $2.36 Million Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
What indicators show strength in Mirum Pharmaceuticals Inc.2025 Growth vs Value & Fast Exit Strategy with Risk Control - Newser
Can Mirum Pharmaceuticals Inc. sustain its profitabilityMarket Activity Summary & Advanced Technical Signal Analysis - خودرو بانک
Mirum Pharmaceuticals stock reaches all-time high of 75.8 USD - Investing.com
Does Mirum Pharmaceuticals Inc. show high probability of reboundJuly 2025 Spike Watch & Verified Swing Trading Watchlist - Newser
Forecasting Mirum Pharmaceuticals Inc. price range with options dataPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
Tema Etfs LLC Sells 30,536 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. impacted by rising ratesSwing Trade & Real-Time Buy Zone Alerts - خودرو بانک
Is Mirum Pharmaceuticals Inc. showing signs of accumulationMarket Movement Recap & High Accuracy Buy Signal Tips - Newser
Does Mirum Pharmaceuticals Inc. have strong fundamentalsJuly 2025 Breakouts & Risk Managed Investment Strategies - خودرو بانک
How high can Mirum Pharmaceuticals Inc. stock goEarnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
What are Mirum Pharmaceuticals Inc.’s earnings expectationsPortfolio Growth Summary & High Conviction Buy Zone Alerts - خودرو بانک
Strategies to average down on Mirum Pharmaceuticals Inc.July 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Alagille Syndrome Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Takeda, Mirum Pharmaceuticals, Albireo - Barchart.com
How to interpret RSI for Mirum Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Volume Analysis - Newser
What indicators show strength in Mirum Pharmaceuticals IncWeekly Trend Report & Capital Efficiency Focused Strategies - Newser
Applying big data sentiment scoring on Mirum Pharmaceuticals Inc.July 2025 Decliners & Fast Entry Momentum Alerts - Newser
Next Century Growth Investors LLC Buys 31,089 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. stock forming a triangle pattern2025 Major Catalysts & Advanced Technical Analysis Signals - خودرو بانک
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):